newsfilter
← Latest News
GlobeNewswire·

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today